An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Neil L. Spector, Takuya Osada et al.|Breast Cancer Research|2013Cited by 146
Abstract PD9-04: Identification of biomarkers associated with therapeutic resistance: Quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancerJulia Wulfkuhle, Emanual Petricoin, Denise Wolf et al.|Cancer Research|2021Cited by 0